Translational and Clinical Research Program

点击翻译按钮获取中文摘要

The Siteman Cancer Center (SCC) combines excellence in clinical research, patient care and basic science to foster an environment in which novel solutions are developed for cancer-related health problems. The structure of the Translational and Clinical Research program is designed to maximize these discoveries by establishing an infrastructure for highly productive interchange between investigators in the basic science of malignancy, oncologic imaging, prevention and control and clinical trial development. During the previous three-year award period, the Translational and Clinical Research Program developed a paradigm for integrating basic science research programs with disease-oriented focus groups, producing interdisciplinary, highly translational programs that will ultimately produce multi-project grants, such as Program Project Grants (P01s) or SPOREs. This is demonstrated through the development of the newly-named Hematopoietic Development and Malignancy Program, which has united the old Stem Cell Biology Program and the Leukemia/Lymphoma/Transplant Focus Group of this program. The goals of the Translational and Clinical Research Program are as follows: ¿ To develop new translational research programs that will ultimately produce multi-project grants (such as SPOREs and P01s) through the integration of Focus Groups with the Basic Science, Prevention and Control, and Oncologic Imaging Programs. ¿ To develop, prioritize and execute novel investigator-initiated clinical trials with a particular emphasis on translational research that involves collaborators from the Basic Science, Prevention and Control, and Oncologic Imaging programs and is driven by the four central scientific themes of cancer genetics, cancer biology and development, innovative diagnostics and therapeutics, and chemoprevention. ¿ To participate in important NCI-sponsored clinical trials addressing questions that can only be answered in the setting of multi-institutional Phase III trials. ¿ To collaborate with members of the pharmaceutical industry to develop and test novel compounds that require pharmacologic and molecular expertise that can be uniquely provided by the SCC. ¿ To develop multidisciplinary clinical care and research programs that encourage contribution from all members of the oncology professional community (treating physicians, basic science researchers, psychologists, nurses, etc.).